<DOC>
	<DOCNO>NCT00744809</DOCNO>
	<brief_summary>This study evaluate effect TMC278 25 mg daily QT/QTc interval ( heart conduction heart rhythm ) healthy volunteer . In separate panel healthy volunteer , effect efavirenz ( EFV ) 600 mg daily QT/QTc interval evaluate .</brief_summary>
	<brief_title>TMC278-TiDP6-C152 : A Study Assess Effects TMC278 Efavirenz ( EFV ) QT/QTc Interval ( Heart Conduction Heart Rhythm ) Healthy Volunteers .</brief_title>
	<detailed_description>This trial evaluate effect TMC278 25 mg daily QT/QTc interval ( heart conduction heart rhythm ) healthy volunteer . In separate panel healthy volunteer , effect efavirenz ( EFV ) 600 mg daily QT/QTc interval evaluate . TMC278 investigate treatment HIV-1 infection . In one panel , effect TMC278 steady-state QT/QTc interval healthy volunteer evaluate double-blind ( neither doctor patient know patient get active drug placebo ) , randomize ( study drug assign chance ) , placebo control positive control 3-way crossover design . One dose regimen 25 mg daily TMC278 test 11 day . In second session , single dose 400 mg moxifloxacin use positive control assess trial sensitivity . A placebo session include reference . In separate panel , effect EFV steady-state QT/QTc interval healthy volunteer evaluate double-blind , randomize , placebo control 2-way crossover design . One dose regimen 600 mg daily EFV test 11 day . Similar TMC278 panel , placebo session include reference . The overall trial population consist 120 healthy volunteer least 30 % 50 % female least 20 % non-Hispanic Caucasians . Patients randomize 1:1 ratio either TMC278 panel EFV panel . The randomization 2 panel stratify gender ethnicity randomization within panel stratify gender . Each patient TMC278 panel receive 3 session random order : TMC278 25 mg daily Day 1-11 moxifloxacin placebo q.d . Day 11 ( Treatment A ) , TMC278 placebo daily Day 1-11 moxifloxacin placebo q.d . Day 11 ( Treatment B ) , TMC278 placebo daily Day 1-11 moxifloxacin 400 mg q.d . Day 11 ( Treatment C ) . All intake TMC278 , moxifloxacin , TMC278 placebo moxifloxacin placebo feed condition take place supervision unit . There washout period least 21 day consecutive treatment . Each patient EFV panel receive 2 session random order : EFV 600 mg daily 11 day ( Treatment D ) EFV placebo q.d . 11 day ( Treatment E ) . All intake EFV EFV placebo fast condition take place supervision unit . There washout period least 53 day 2 treatment . In TMC278 EFV panel , ECGs record continuously 24 hour Holter monitor Day -1 Day 11 treatment session . In addition , safety monitoring , 12-lead ECGs perform predefined time point . Pharmacokinetic sample collect Day -1 , Day 9 , Day 10 , Day 11 , within 5 minute safety ECG record Holter extraction time point , applicable , determination TMC278 , moxifloxacin EFV plasma concentration , appropriate . Safety tolerability monitor throughout trial . In TMC278 Panel , TMC278 placebo give mouth Days 1-11 Moxifloxican placebo give mouth Day 11 . Patients return washout period total 3 cycle . In EFV Panel , EFV placebo give mouth Days 1-11 . Patients return washout period total 2 cycle .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Patients must : nonsmoker ( tobacco product , nicotine nicotine containing product kind least 1 year ) Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include healthy basis pretrial physical examination , medical history , electrocardiogram , vital sign result routine blood urine test screen normal 12lead ECG screen Day 1 ( safety ECG ) first treatment period . Patients must : positive HIV1 2 test trial screen female childbearing potential without use effective birth control method willing continue practice birth control method screen onwards least 30 day last intake trial medication history evidence current use alcohol , barbiturate , amphetamine , recreational , narcotic drug use Hepatitis A , B C infection trial screen participate investigational drug trial within 60 day prior first intake trial medication history clinically relevant heart rhythm disturbance blood pressure ( BP ) outside normal range ( sit systolic blood pressure &lt; 90 &gt; 140 mmHg and/or diastolic blood pressure &lt; 40 &gt; 90 mmHg ) screen Day 1 first treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>TMC278-C152</keyword>
	<keyword>TMC278-TiDP6-C152</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>QT/QTc interval</keyword>
</DOC>